Abivax has appointed Michael Nesrallah as its chief commercial officer, putting one of the people who turned Takeda’s Entyvio ...

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis. The results are ...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory ...

Entyvio (vedolizumab) is a prescription drug that’s used to treat ulcerative colitis and Crohn’s disease. It’s not known whether Entyvio is safe to use while pregnant or breastfeeding. If you can ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with ulcerative colitis were more likely to ...

Please provide your email address to receive an email when new articles are posted on . Entyvio therapy may improve disease course of immune-mediated diarrhea colitis and decrease steroid exposure, ...

In May, the U.S. Food and Drug Administration (FDA) simultaneously approved Entyvio for the treatment of adults with moderately to severely active UC and CD. That same month, Entyvio was also granted ...

EXTON, Pa., June 8, 2021 /PRNewswire/ — A few months after the European Medicines Agency (EMA) approved Takeda’s subcutaneous formulation of Entyvio, known as Entyvio SC, Spherix captured the initial ...

Studies, presented at the 25th UEG Week, demonstrated the effectiveness of Takeda’s Entyvio in treating ulcerative colitis and Crohn’s disease, IBD News Today reports. From May 2014 to January 2017, ...

DEERFIELD, Ill. — Takeda Pharmaceutical on Tuesday announced that the Food and Drug Administration simultaneously approved a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults ...